Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial (Q34856640)

4 August 2017

title

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial (English)

1 reference

4 August 2017

1 reference

2

Robert S Sandler

1 reference

4 August 2017

John A Baron

1

1 reference

4 August 2017

Robert S Bresalier

3

1 reference

4 August 2017

Angel Lanas

4

1 reference

4 August 2017

Dion G Morton

5

1 reference

4 August 2017

Robert Riddell

6

1 reference

4 August 2017

Erik R Iverson

7

1 reference

4 August 2017

David L Demets

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

14 October 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

372

1 reference

4 August 2017

issue

9651

1 reference

4 August 2017

page(s)

1756-1764

1 reference

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Epidemiology of non-steroidal anti-inflammatory drugs and cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Adverse cardiovascular effects of rofecoxib

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Time-to-Event Analyses for Long-Term Treatments — The APPROVe Trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(08)61490-7

7 January 2021

10.1016/S0140-6736(08)61490-7

Identifiers

DOI

1 reference

4 August 2017

1 reference